SR-2508

Known as: SR 2508, SR2508 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1980-2007
05101519802007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
The pharmacokinetics of cyclophosphamide (CP) and several important metabolites was studied in detail in six patients receiving… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
1991
1991
Following the completion of a phase I study of etanidazole (SR 2508), a new hypoxic cell sensitizer, the RTOG, began a phase II… (More)
Is this relevant?
1991
1991
The two current second generation radiosensitizers SR-2508 (etanidazole) and Ro 03-8799 (pimonidazole) have different dose… (More)
Is this relevant?
1991
1991
SR-2508, a less lipophilic ane neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1987
1987
Complete pharmacological data from 71 patients treated on the phase I trial of SR 2508 were analyzed to see if the dose-limiting… (More)
  • table 1
  • figure 2
  • figure 1
Is this relevant?
1986
1986
Sixty-five patients were entered on the long schedule of the Phase I trial of SR-2508. The planned total doses ranged from 30 to… (More)
Is this relevant?
1986
1986
Misonidazole, SR-2508 and Ro 03-8799 have been given in sequence to patients before tumor sampling. Tumor concentrations of the… (More)
Is this relevant?
1984
1984
Depletion of intracellular glutathione (GSH) can enhance misonidazole (MISO) radiosensitizing efficacy both in vivo and in vitro… (More)
Is this relevant?
1984
1984
From March 15, through August 31, 1983, 37 patients have been entered on the RTOG Phase I trial of SR-2508. The drug was given… (More)
Is this relevant?
1984
1984
We have used the RIF-1 tumor implanted intradermally in the lower dorsum of C3H mice to explore to what extent the… (More)
Is this relevant?